Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease
Sponsor: Amylin Pharmaceuticals, LLC.
Terminated
Lack of recruitment
Other terminated trials from Amylin Pharmaceuticals, LLC.
- Bone Remodeling · Phase PHASE4 · Aug 2015
- Type 1 Diabetes · Phase PHASE1 · Aug 2014
- Type 1 Diabetes · Phase NA · Nov 2011
More terminations from Amylin Pharmaceuticals, LLC.
Other Diabetes Complications trials with similar outcome
A PHASE2 clinical study on Diabetes Complications and Fatty Liver, this trial is terminated or withdrawn. The trial is conducted by Amylin Pharmaceuticals, LLC. and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amylin Pharmaceuticals, LLC.
- Eli Lilly and Company
- University of California, Davis
For direct contact, visit the study record on ClinicalTrials.gov .